Advertisement
Australia markets open in 7 hours 1 minute
  • ALL ORDS

    8,272.70
    -30.80 (-0.37%)
     
  • AUD/USD

    0.6727
    -0.0006 (-0.08%)
     
  • ASX 200

    8,036.50
    -21.40 (-0.27%)
     
  • OIL

    83.17
    +0.32 (+0.39%)
     
  • GOLD

    2,461.00
    +1.10 (+0.04%)
     
  • Bitcoin AUD

    95,005.73
    -507.31 (-0.53%)
     
  • CMC Crypto 200

    1,324.20
    -5.30 (-0.40%)
     

Midday movers: Home Depot, Capital One Financial, Tesla and more

Investing.com -- Stocks were mixed at midday Tuesday as investors waited for clarity on the direction of negotiations over raising the debt ceiling, with a June 1 deadline just weeks away. Here are the market movers for May 16.

Home Depot Inc (NYSE:HD) shares fell 1.4% after the home improvement retailer reported weaker-than-expected sales for the first quarter and lowered its outlook for the year as shoppers cut down on spending. Same-store sales fell 4.5%. Capital One Financial Corporation (NYSE:COF) shares rose 2.4% after Warren Buffett's Berkshire Hathaway (NYSE:BRKa) disclosed it had taken on a new 9.9 million share position in the card company as of the end of the first quarter. Tesla Inc (NASDAQ:TSLA) shares were up 1.3% in anticipation of the electric vehicle maker's annual shareholder meeting this afternoon. Earlier, billionaire George Soros' fund disclosed it no longer had a stake in the company. Horizon Therapeutics PLC (NASDAQ:HZNP) shares were falling 15% after the Federal Trade Commission sued to block its $28 billion acquisition by pharma company Amgen Inc (NASDAQ:AMGN).

Newell Brands Inc (NASDAQ:NWL) shares fell 3.6% after the maker of Rubbermaid and other household products cut its dividend by 70%. Last month, Newell disappointed with a wider-than-expected loss in the first quarter and a below-forecast second-quarter profit projection.

Related Articles

ADVERTISEMENT

Midday movers: Home Depot, Capital One Financial, Tesla and more

Bridgewater dumps bank stocks amid turmoil in first quarter -filings

US FTC sues to block Amgen's $27.8 billion deal for Horizon Therapeutics